Pharma & Biotech

BioNTech is entering a stretch where the story is being reshaped on two fronts at once: the numbers and the...

The market has delivered a brutal verdict on Spero Therapeutics' corporate reinvention. Shares in the biotech group have tumbled roughly...

There is a peculiar arithmetic at work in Alnylam Pharmaceuticals' stock right now: the company just delivered its first-ever quarterly...

The narrative that has defined Bayer for half a decade is finally shifting. For years, the chemicals-to-pharma group was the...

Pentixapharm has packed a remarkable amount of activity into recent days. The radiopharmaceutical specialist is juggling a US regulatory milestone...

Bayer’s share price stalled on Wednesday, sliding 2.97 percent to €47.70, as a raft of crosscurrents pulled the stock off...

Evotec’s second profit warning in just four months has thrown the credibility of the Hamburg-based biotech into sharp relief, with...

Bayer is weaving together legal, financial, and trade initiatives at a pace that suggests a coordinated push to close the...

Ugur Sahin and Özlem Türeci built BioNTech from a Mainz lab into a global vaccine powerhouse. By the end of...

Bayer unleashed a flurry of strategic moves over the weekend that simultaneously strengthen its balance sheet, attack its biggest legal...